Overview

Effects of Coenzyme Q10 in PSP and CBD

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
0
Participant gender:
All
Summary
To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Lahey Clinic
Treatments:
Coenzyme Q10
Ubiquinone
Criteria
Inclusion Criteria:

- Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were
diagnosed within the past 5 years

- Age > 40

- Subjects receiving anticholinergics, amantadine, dopamine agonists,
carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days
prior to baseline visit.

- Patients agreeable to participate in the study.

Exclusion Criteria:

- Prior or concurrent therapy with anticholinergics, amantadine,a dopamine
agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.

- Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.

- History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue
transplant.

- Previous use of coenzyme Q10 within 60 days of the baseline visit.